Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Have a diagnosis of definite akylosing spondylitis for at least 3 months~* Have symptoms of active disease at screening and at baseline~* no active infections~Exclusion Criteria:~* Have other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy~* Have complete ankylosis of the spine~* Have a history of latent or active granulomatous infection~* Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): None
- Golimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).